 ALEX HOGAN/STAT |
Today is a big news day for STAT, and for anyone interested in health and medicine, as seven pharma executives take part in a televised cross examination on high prescription drug prices before a powerful Senate committee.
Our D.C. reporters are on the scene, chronicling the event and chasing down lawmakers and pharma executives for their insights afterward. We also stand ready to give you fact checks of the testimony, and to jump on any move that sends stocks tumbling.
Already, STAT has doggedly covered the run-up. Late yesterday, our reporter Nick Florko tracked down senators to find out their burning questions. We have also offered a lively guide to the quirks, qualifications, and questionable decisions each company leader will bring to the Senate and an inside look at how pharma execs are preppingto avoid political disaster.
You can also sign up for our (free) webinar tomorrow that will debrief on today’s hearing and delve into whether the new Congress is ready to lower drug costs.
The stories leading up to the hearing are only a snapshot of the all-encompassing coverage we have delivered on drug pricing in the past three years. We've covered how the 2020 presidential candidates are scrambling to be the champion of slashing drug prices, and we've looked deeply into the legislative and pricing strategies of the drug industry.
Our First Opinion section has been a forum for provocative pieces on drug pricing, including HHS Secretary Alex Azar on why drug prices keep going up, and how pharmacy benefit managers may be scaring seniors about Medicare Part D.
For even more, you can buy a subscription to STAT Plus, which dives deeper into drug pricing, including the nitty-gritty of the Trump administration's proposals.
Thanks, as always, for reading STAT and please reach out if you have any thoughts or suggestions. I'm at rick.berke@statnews.com.
No hay comentarios:
Publicar un comentario